The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study).
 
Guoming Shi
No Relationships to Disclose
 
Xiaoyong Huang
No Relationships to Disclose
 
Tianfu Wen
No Relationships to Disclose
 
Tianqiang Song
No Relationships to Disclose
 
Ming Kuang
No Relationships to Disclose
 
Haibo Mou
No Relationships to Disclose
 
Lequn Bao
No Relationships to Disclose
 
Hai-Tao Zhao
No Relationships to Disclose
 
Hong Zhao
No Relationships to Disclose
 
Xielin Feng
No Relationships to Disclose
 
Bixiang Zhang
No Relationships to Disclose
 
Tao Peng
No Relationships to Disclose
 
Yubao Zhang
No Relationships to Disclose
 
Xiangcheng Li
No Relationships to Disclose
 
Hongsheng Yu
No Relationships to Disclose
 
Yu Cao
No Relationships to Disclose
 
Yang Luo
Employment - Innovent Biologics
 
Mingxia Chen
Employment - Innovent Biologics
 
Jia Fan
No Relationships to Disclose
 
Jian Zhou
No Relationships to Disclose